MarketPulse
I

$INBX

1 article found
1 positive
0 negative
0 neutral
BenzingaBenzinga··Vandana Singh

Big Pharma Circles Inhibrx Cancer Assets in $9B Spin-Off Deal

Inhibrx is fielding takeover interest from major pharma for cancer drug INBRX-106 in potential $9B spin-off; stock surges 39.86%.
JNJMRKPFELLYSNY+2biotechclinical trials